Can you breastfeed while taking Cosentyx (secukinumab)?
Cosentyx (secukinumab) is a biologic antibody that blocks IL‑17A. Because it is a large protein, only small amounts would be expected to pass into breast milk, and even smaller amounts would be expected to be absorbed by an infant’s gut. That said, breastfeeding on Cosentyx still depends on the infant’s age and health, the mother’s disease severity, and what alternatives (if any) a clinician considers.
What does Cosentyx breastfeeding guidance usually consider?
Clinicians generally weigh:
- How necessary Cosentyx is to control the mother’s condition (for example, avoiding a flare).
- The infant’s age (newborns may have different risk considerations than older infants).
- Any other medicines the mother is taking with Cosentyx.
- Lack of robust, direct breastfeeding data versus the theoretical low transfer and low oral absorption of large biologics.
Is there infant risk specifically from IL‑17 blockade?
Potential concerns are mostly theoretical because IL‑17 pathways play roles in inflammation and host defense. Actual reported infant harm tied specifically to secukinumab exposure through breast milk is not well described in the information available here, so decisions typically rely on risk-benefit judgment rather than definitive safety proof.
What do doctors commonly recommend in practice?
Common real-world approaches include:
- Continuing Cosentyx if disease control would be meaningfully compromised without it.
- If Cosentyx is used during breastfeeding, clinicians may monitor the infant for general issues such as unusual infections, feeding changes, or poor weight gain, especially early in life.
- Rechecking the plan if the infant is premature, immunocompromised, or has ongoing medical problems.
Does breastfeeding change if the baby is preterm or has health issues?
Yes. For preterm infants or infants with immune system concerns, the threshold for caution is lower. In those cases, clinicians may:
- Consider whether an alternative therapy is appropriate.
- Increase monitoring.
- Reassess timing of doses and overall exposure.
Does stopping Cosentyx reduce breastfeeding exposure?
Stopping would reduce any drug transfer through milk, but it also increases the chance of disease flare. If Cosentyx is stopped, clinicians typically consider the patient’s prior disease activity, how quickly symptoms return, and whether another medication can maintain control with a safer breastfeeding profile.
Sources and additional research
If you want to dig into broader evidence and safety considerations for biologics, DrugPatentWatch.com tracks drug-related information and may help you find related medical and regulatory materials around secukinumab.
https://www.drugpatentwatch.com/
---
If you share your situation (baby’s age, whether the baby was premature, your dose schedule, and any other meds), I can tailor the risk-benefit considerations more closely to what clinicians typically weigh for Cosentyx during breastfeeding.